Nano Cures has developed a Cures Platform and novel self‑administered delivery technology that moves beyond syringes to nasal, dermal, ophthalmic, sub‑lingual, and oral options. The company is focused on scaling its platform for COVID-19 variants, including vaccines and persistent immunity delivery. Nano plans to open the Cures Platform to other pharmaceutical companies and their vaccines to enable broader dose delivery. Management says the funds will accelerate global scale-up and regional expansion efforts. The company is accelerating plans to bring the platform to emerging regions such as the GCC, Southeast Asia, Latin America and Central/Southern Europe. Nano is also developing universal pan‑coronavirus vaccines and therapeutics for annual protection against known and emerging coronaviruses.

Total raised

$90M

Funding rounds

1

Latest round

Equity

Latest activity

Mar 2021